This update was written automatically with AI from market data and news wire reports, and published without review by a person.
Key Takeaways
- Capricor Therapeutics (CAPR) shares plummeted over 80% in extended trading after the FDA rejected its BLA for Deramiocel, citing "serious deficiencies" in clinical trial conduct.
- Defense Secretary Pete Hegseth issued a classified directive restricting U.S. defense cooperation with Canada, a move described by officials as a "slap in the face" to the long-standing ally.
- The FDA identified "unreliable" data in the HOPE-3 study that cannot be rectified post-trial, involving unauthorized changes to statistical analyses and violations of trial blinding.
- U.S. intelligence sharing and NORAD collaboration are reportedly excluded from the new defense restrictions, though broader military ties face significant curtailment.
- Capricor maintains $198.5 million in cash as of late 2026, which it claims provides a 12-month runway despite the massive regulatory setback.
FDA Issues Complete Response Letter to Capricor Therapeutics
The U.S. Food and Drug Administration (FDA) has officially rejected the Biologics License Application (BLA) for Deramiocel, an investigational cell therapy developed by Capricor Therapeutics (CAPR) for Duchenne muscular dystrophy (DMD). In a rare public statement accompanying the Complete Response Letter (CRL), the regulator stated that the evidence provided did not meet the "substantial evidence of effectiveness" required for approval.
The rejection was primarily driven by serious data integrity issues discovered during a Bioresearch Monitoring (BIMO) inspection of the HOPE-3 study. The FDA noted that Capricor made unauthorized changes to statistical analysis plans after the study began and violated trial blinding procedures, rendering the resulting data unreliable and "incapable of post hoc remediation."
Following the news, Capricor (CAPR) shares crashed by more than 80% in after-hours trading, falling from a daily high of $8.94 to approximately $1.48. While CEO Linda Marbán expressed deep disappointment and stood by the "rigor" of the clinical program, the company is now forced to review its operating costs and evaluate the future of its lead experimental asset.
Hegseth Memo Escalates Tensions with Canada
In a separate geopolitical development, Defense Secretary Pete Hegseth has imposed new restrictions on the U.S.-Canada defense relationship via a classified memo. The directive marks a significant escalation in the ongoing friction between the Trump administration and Ottawa, coming on the heels of repeated threats regarding trade and territorial annexation.
While the specific nature of the restrictions remains classified, a Pentagon spokesman clarified that the directive will not impact defense intelligence sharing or collaboration through NATO and NORAD. Instead, the Pentagon is reportedly "prioritizing opportunities" that specifically advance "tangible U.S. defense objectives" and pressure Canada to meet its NATO spending obligations.
The move has been met with concern from defense officials, who warn that curtailing interactions between the two militaries could damage a foundational security partnership. The Canadian embassy has yet to issue a formal comment, though the restrictions are widely viewed by analysts as a strategic "slap in the face" intended to force concessions from Prime Minister Mark Carney’s government.
Market Implications and Data Integrity Scrutiny
The dual blow of clinical trial failures and shifting geopolitical alliances has introduced fresh volatility into the biotechnology and defense sectors. The FDA’s aggressive stance on the HOPE-3 study highlights a broader regulatory trend of increased scrutiny toward data integrity, particularly for therapies targeting rare diseases where evidentiary standards are often debated.
For Capricor (CAPR, the path forward remains highly uncertain as the agency indicated that the identified trial deficiencies cannot be fixed retrospectively. Investors are now focused on the company's remaining $198.5 million cash reserve and whether a new, more rigorous Phase 3 trial will be required to salvage the Deramiocel program.
Meanwhile, the Hegseth directive may signal a shift in how the U.S. manages bilateral defense contracts and joint procurement programs with Canada. Market participants in the defense sector are closely watching for any signs that these restrictions could extend to industrial cooperation or cross-border supply chains for critical military hardware.
Automated market updates written with AI from market data and news wire reports, published without human review.